Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis (HINT)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
National Multiple Sclerosis Society
Information provided by (Responsible Party):
University of Wisconsin, Madison
ClinicalTrials.gov Identifier:
NCT00645749
First received: March 25, 2008
Last updated: October 9, 2015
Last verified: October 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: March 2017
  Estimated Primary Completion Date: March 2017 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):